Solid Sales and Core Operating Income Growth
Novartis delivered a 7% increase in sales and core operating income, maintaining a core margin of 39.3%.
Strong Performance of Key Brands
Kisqali grew 68%, Kesimpta 44%, Pluvicto 45%, and Scemblix 95%, with robust growth across multiple markets.
FDA Approvals and Positive Pipeline Results
Important approvals include Rhapsido for CSU, with positive Phase III results for Ianalumab and Pluvicto, among others.
Free Cash Flow and Capital Allocation
Free cash flow reached $16 billion for the first nine months, enabling significant reinvestment and shareholder returns.
2025 Guidance Reaffirmed
The company expects high single-digit sales growth and low teens growth in core operating income for the full year.